49 - Genetics and Pathophysiology of Cystic Fibrosis

Garry R Cutting, John Engelhardt, Pamela Leslie Zeitlin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Our understanding of the role of disease-causing variants in CFTR has culminated in two new variant-specific CFTR modulator therapies approved by the US FDA. These modulators target defects in CFTR biogenesis and in channel gating. Clinical trials are directed to improving the efficacy of these first-generation molecules. However, other CFTR variants that lead to nonsense-mediated decay, aberrant splicing, and reduced gene expression are refractory to CFTR modulators and will require new therapeutic approaches. To this end, new CF animal models are yielding key insights into tissue-specific disease mechanisms, such as impaired mucociliary clearance and pancreatic dysfunction. Although infection and inflammation remain challenging to treat, progress in targeting CFTR directly will result in individuals with CF living longer. To maximize life span, earlier interventions, soon after diagnosis, are needed. Finally, the advances in precision medicine for CF may benefit more common disorders such as COPD and pancreatitis where CFTR dysfunction contributes to pathophysiology.

Original languageEnglish (US)
Title of host publicationKendig's Disorders of the Respiratory Tract in Children
PublisherElsevier Inc.
Pages757-768.e6
ISBN (Electronic)9780323555951
ISBN (Print)9780323448871
DOIs
StatePublished - Mar 8 2018

Fingerprint

Cystic Fibrosis
Mucociliary Clearance
Precision Medicine
Pancreatitis
Chronic Obstructive Pulmonary Disease
Animal Models
Clinical Trials
Inflammation
Gene Expression
Therapeutics
Infection

Keywords

  • CFTR
  • Chloride
  • DNA variant
  • Nonsense-mediated decay
  • Protein folding
  • Sodium
  • Splicing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cutting, G. R., Engelhardt, J., & Zeitlin, P. L. (2018). 49 - Genetics and Pathophysiology of Cystic Fibrosis. In Kendig's Disorders of the Respiratory Tract in Children (pp. 757-768.e6). Elsevier Inc.. https://doi.org/10.1016/B978-0-323-44887-1.00049-3

49 - Genetics and Pathophysiology of Cystic Fibrosis. / Cutting, Garry R; Engelhardt, John; Zeitlin, Pamela Leslie.

Kendig's Disorders of the Respiratory Tract in Children. Elsevier Inc., 2018. p. 757-768.e6.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cutting, GR, Engelhardt, J & Zeitlin, PL 2018, 49 - Genetics and Pathophysiology of Cystic Fibrosis. in Kendig's Disorders of the Respiratory Tract in Children. Elsevier Inc., pp. 757-768.e6. https://doi.org/10.1016/B978-0-323-44887-1.00049-3
Cutting GR, Engelhardt J, Zeitlin PL. 49 - Genetics and Pathophysiology of Cystic Fibrosis. In Kendig's Disorders of the Respiratory Tract in Children. Elsevier Inc. 2018. p. 757-768.e6 https://doi.org/10.1016/B978-0-323-44887-1.00049-3
Cutting, Garry R ; Engelhardt, John ; Zeitlin, Pamela Leslie. / 49 - Genetics and Pathophysiology of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier Inc., 2018. pp. 757-768.e6
@inbook{813ce09878b34a1b96ba22520bbccf56,
title = "49 - Genetics and Pathophysiology of Cystic Fibrosis",
abstract = "Our understanding of the role of disease-causing variants in CFTR has culminated in two new variant-specific CFTR modulator therapies approved by the US FDA. These modulators target defects in CFTR biogenesis and in channel gating. Clinical trials are directed to improving the efficacy of these first-generation molecules. However, other CFTR variants that lead to nonsense-mediated decay, aberrant splicing, and reduced gene expression are refractory to CFTR modulators and will require new therapeutic approaches. To this end, new CF animal models are yielding key insights into tissue-specific disease mechanisms, such as impaired mucociliary clearance and pancreatic dysfunction. Although infection and inflammation remain challenging to treat, progress in targeting CFTR directly will result in individuals with CF living longer. To maximize life span, earlier interventions, soon after diagnosis, are needed. Finally, the advances in precision medicine for CF may benefit more common disorders such as COPD and pancreatitis where CFTR dysfunction contributes to pathophysiology.",
keywords = "CFTR, Chloride, DNA variant, Nonsense-mediated decay, Protein folding, Sodium, Splicing",
author = "Cutting, {Garry R} and John Engelhardt and Zeitlin, {Pamela Leslie}",
year = "2018",
month = "3",
day = "8",
doi = "10.1016/B978-0-323-44887-1.00049-3",
language = "English (US)",
isbn = "9780323448871",
pages = "757--768.e6",
booktitle = "Kendig's Disorders of the Respiratory Tract in Children",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - 49 - Genetics and Pathophysiology of Cystic Fibrosis

AU - Cutting, Garry R

AU - Engelhardt, John

AU - Zeitlin, Pamela Leslie

PY - 2018/3/8

Y1 - 2018/3/8

N2 - Our understanding of the role of disease-causing variants in CFTR has culminated in two new variant-specific CFTR modulator therapies approved by the US FDA. These modulators target defects in CFTR biogenesis and in channel gating. Clinical trials are directed to improving the efficacy of these first-generation molecules. However, other CFTR variants that lead to nonsense-mediated decay, aberrant splicing, and reduced gene expression are refractory to CFTR modulators and will require new therapeutic approaches. To this end, new CF animal models are yielding key insights into tissue-specific disease mechanisms, such as impaired mucociliary clearance and pancreatic dysfunction. Although infection and inflammation remain challenging to treat, progress in targeting CFTR directly will result in individuals with CF living longer. To maximize life span, earlier interventions, soon after diagnosis, are needed. Finally, the advances in precision medicine for CF may benefit more common disorders such as COPD and pancreatitis where CFTR dysfunction contributes to pathophysiology.

AB - Our understanding of the role of disease-causing variants in CFTR has culminated in two new variant-specific CFTR modulator therapies approved by the US FDA. These modulators target defects in CFTR biogenesis and in channel gating. Clinical trials are directed to improving the efficacy of these first-generation molecules. However, other CFTR variants that lead to nonsense-mediated decay, aberrant splicing, and reduced gene expression are refractory to CFTR modulators and will require new therapeutic approaches. To this end, new CF animal models are yielding key insights into tissue-specific disease mechanisms, such as impaired mucociliary clearance and pancreatic dysfunction. Although infection and inflammation remain challenging to treat, progress in targeting CFTR directly will result in individuals with CF living longer. To maximize life span, earlier interventions, soon after diagnosis, are needed. Finally, the advances in precision medicine for CF may benefit more common disorders such as COPD and pancreatitis where CFTR dysfunction contributes to pathophysiology.

KW - CFTR

KW - Chloride

KW - DNA variant

KW - Nonsense-mediated decay

KW - Protein folding

KW - Sodium

KW - Splicing

UR - http://www.scopus.com/inward/record.url?scp=85054761046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054761046&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-44887-1.00049-3

DO - 10.1016/B978-0-323-44887-1.00049-3

M3 - Chapter

SN - 9780323448871

SP - 757-768.e6

BT - Kendig's Disorders of the Respiratory Tract in Children

PB - Elsevier Inc.

ER -